GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of “Hold” by Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned an average recommendation of “Hold” from the fifteen research firms that are presently covering the stock, Marketbeat reports. Ten analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $8.38.

A number of brokerages have issued reports on GDRX. DA Davidson upgraded shares of GoodRx from a “neutral” rating to a “buy” rating and set a $9.50 price target on the stock in a report on Thursday, August 10th. Guggenheim upped their target price on shares of GoodRx from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, August 10th. The Goldman Sachs Group upped their target price on shares of GoodRx from $6.25 to $7.00 and gave the company a “neutral” rating in a research report on Thursday, August 10th. Evercore ISI upped their target price on shares of GoodRx from $7.00 to $10.00 and gave the company an “in-line” rating in a research report on Thursday, August 10th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on shares of GoodRx from $6.00 to $8.00 and gave the company a “hold” rating in a research report on Thursday, August 10th.

GoodRx Stock Up 0.3 %

GDRX opened at $6.55 on Monday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 11.14 and a current ratio of 11.14. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of 218.33, a price-to-earnings-growth ratio of 7.87 and a beta of 1.06. The firm’s fifty day moving average is $6.82 and its 200 day moving average is $6.00. GoodRx has a fifty-two week low of $3.82 and a fifty-two week high of $9.37.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. The company had revenue of $189.68 million for the quarter, compared to the consensus estimate of $186.90 million. GoodRx had a net margin of 1.58% and a return on equity of 2.44%. On average, sell-side analysts forecast that GoodRx will post 0.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GoodRx

A number of hedge funds have recently added to or reduced their stakes in the stock. Virginia Retirement Systems ET AL bought a new position in GoodRx in the 2nd quarter worth about $571,000. GTS Securities LLC bought a new position in GoodRx in the 2nd quarter worth about $162,000. Woodline Partners LP grew its stake in GoodRx by 10.0% in the 2nd quarter. Woodline Partners LP now owns 675,728 shares of the company’s stock worth $3,730,000 after acquiring an additional 61,278 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in GoodRx in the 2nd quarter worth about $71,000. Finally, Rip Road Capital Partners LP bought a new position in GoodRx in the 2nd quarter worth about $5,333,000. 33.63% of the stock is currently owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.